Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 213-219

  Masana, Luís ^a   Cabré, Anna ^a   Heras, Mercedes ^a   Amigó, Núria ^b   Correig, Xavier ^b   Martínez Hervás, Sergio ^c   Real, José T ^c   Ascaso, Juan F ^c   Quesada, Helena ^e   Julve, Josep ^d,e   Palomer, Xavier ^f   Vázquez Carrera, Manuel ^f   Girona, Josefa ^a   Plana, Núria ^a   Blanco Vaca, Francisco ^d,e  

^a HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^b UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^c UNIVERSITY OF VALENCIA   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CETP; Fenofibrate; HDL; HDL particle size; LCAT; Niacin; Nuclear magnetic resonance; PAF AH; PON1; PON3; Pre 1 HDL; Type 2 diabetes

Indexed keywords

ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL ESTER TRANSFER PROTEIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAROPIPRANT; NICOTINIC ACID; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; SIMVASTATIN; THROMBOCYTE ACTIVATING FACTOR; ANTILIPEMIC AGENT; BIOLOGICAL MARKER; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOLE DERIVATIVE; MK-0524; OXIDIZING AGENT; PRE BETA HIGH DENSITY LIPOPROTEIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DIAGNOSTIC TEST ACCURACY STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; HUMAN; INTERVENTION STUDY; MALE; METABOLOMICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PARTICLE SIZE; PHYSICAL EXAMINATION; PLASMA; PREDICTIVE VALUE; PROSPECTIVE STUDY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; BLOOD; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS, TYPE 2; DRUG COMBINATION; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; PROCEDURES; SPAIN; TIME; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; FENOFIBRATE; HIGH-DENSITY LIPOPROTEINS, PRE-BETA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; INDOLES; MALE; METABOLOMICS; MIDDLE AGED; NIACIN; OXIDANTS; PARTICLE SIZE; PROSPECTIVE STUDIES; SIMVASTATIN; SPAIN; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 84918796117     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.006     Document Type: Article

References (35)

1. Ryden L., Standl E., Bartnik M., et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur. Heart J. 2007, 28:88-136.
2. Perk J., De Backer G., Gohlke H., et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur. Heart J. 2012, 33:1635-1701.
3. Mooradian A.D. Dyslipidemia in type 2 diabetes mellitus. Nat. Clin. Pract. Endocrinol. Metab. 2009, 5:150-159.
4. Chapman M.J., Ginsberg H.N., Amarenco P., et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur. Heart J. 2011, 32:1345-1361.
5. Major lipids, apolipoproteins, and risk of vascular disease. J.Am. Med. Assoc. 2009, 302:1993-2000. The Emerging Risk Factors Collaboration.
6. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861.
7. Robins S.J., Collins D., Wittes J.T., et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591.
8. Effects of combination lipid therapy in type 2 diabetes mellitus. N.Engl. J. Med. 2010, 362:1563-1574. The ACCORD Study Group.
9. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N.Engl. J. Med. 2011, 365:2255-2267. The AIM-HIGH Investigators.
10. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 2013, 34:1279-1291. HPS2-THRIVE Collaborative Group.
11. Vaisar T., Pennathur S., Green P.S., et al. Shotgun proteomics implicates protease inhibition and complement activation in the anti inflammatory properties of HDL. J.Clin. Invest. 2007, 117:746-756.
12. Davidson W.S., Silva R.A., Chantepie S., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler. Thromb. Vasc. Biol. 2009, 29:870-876.
13. Kontush A., Lhomme M., Chapman M.J. Unraveling the complexities of the HDL lipidome. J.Lipid Res. 2013, 54:2950-2963.
14. Camont L., Lhomme M., Rached F., et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler. Thromb. Vasc. Biol. 2013, 33:2715-2723.
15. Kontush A., Chapman M.J. Why is HDL functionally deficient in type 2 diabetes?. Curr. Diab Rep. 2008, 8:51-59.
16. Soran H., Hama S., Yadav R., et al. HDL functionality. Curr. Opin. Lipidol. 2012, 23:353-366.
17. Escola-Gil J.C., Cedo L., Blanco-Vaca F. High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?. Expert Opin. Drug Discov. 2014, 9:119-124.
18. Morgantini C., Natali A., Boldrini B., et al. Anti-inflammatory and antioxidant properties of HDLs are impaired in type 2 diabetes. Diabetes 2011, 60:2617-2623.
19. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N.Engl. J. Med. 2011, 364:127-135.
20. Girona J., Manzanares J.M., Marimon F., et al. Oxidized to non-oxidized lipoprotein ratios are associated with arteriosclerosis and the metabolic syndrome in diabetic patients. Nutr. Metab. Cardiovasc Dis. 2008, 18:380-387.
21. Goldstein D.E., Little R.R., Lorenz R.A., et al. Tests of glycemia in diabetes. Diabetes Care 1995, 18:896-909.
22. Lussier-Cacan S., Xhignesse M., Piolot A., et al. Plasma total homocysteine in healthy subjects: sex-specific relation with biological traits. Am. J. Clin. Nutr. 1996, 64:587-593.
23. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Meth. Enzymol. 1986, 128:155-170.
24. Aragones G., Guardiola M., Barreda M., et al. Measurement of serum PON-3 concentration: method evaluation, reference values, and influence of genotypes in a population-based study. J.Lipid Res. 2011, 52:1055-1061.
25. Marsillach J., Aragones G., Beltran R., et al. The measurement of the lactonase activity of paraoxonase-1 in the clinical evaluation of patients with chronic liver impairment. Clin. Biochem. 2009, 42:91-98.
26. Gaidukov L., Tawfik D.S. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity. J.Lipid Res. 2007, 48:1637-1646.
27. Ribas V., Sanchez-Quesada J.L., Anton R., et al. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential. Circ. Res. 2004, 95:789-797.
28. Mallol R., Rodriguez M.A., Heras M., et al. Particle size measurement of lipoprotein fractions using diffusion-ordered NMR spectroscopy. Anal. Bioanal. Chem. 2012, 402:2407-2415.
29. Fleiss J.L. The crossover study. The Design and Analysis of Clinical Experiments 1986, Wiley, New York. first ed.
30. Villines T.C., Kim A.S., Gore R.S., et al. Niacin: the evidence, clinical use, and future directions. Curr. Atheroscler. Rep. 2012, 14:49-59.
31. Noonan J.E., Jenkins A.J., Ma J.X., et al. An update on the molecular actions of fenofibrate and its clinical effects on diabetic retinopathy and other microvascular end points in patients with diabetes. Diabetes 2013, 62:3968-3975.
32. Taskinen M.R., Sullivan D.R., Ehnholm C., et al. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. Arterioscler. Thromb. Vasc. Biol. 2009, 29:950-955.
33. Guey L.T., Pullinger C.R., Ishida B.Y., et al. Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease. Am. J. Cardiol. 2011, 108:360-366.
34. Hirayama S., Miida T., Miyazaki O., et al. Pre beta1-HDL concentration is a predictor of carotid atherosclerosis in type 2 diabetic patients. Diabetes Care 2007, 30:1289-1291.
35. Julve J., Escola-Gil J.C., Rotllan N., et al. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome. Arterioscler. Thromb. Vasc. Biol. 2010, 30:232-238.